Barclays raised the firm’s price target on C4 Therapeutics (CCCC) to $7 from $5 and keeps an Overweight rating on the shares. The firm says the company’s execution continues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating
- C4 Therapeutics reports Q4 EPS (18c), consensus (34c)
- C4 Therapeutics price target raised to $30 from $20 at Brookline
- C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial
- CCCC Upcoming Earnings Report: What to Expect?